Plaque psoriasis: no difference in drug survival for ixekizumab, secukinumab

  • J Am Acad Dermatol

  • International Clinical Digest
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • A comparative study found no statistically significant difference in drug survival between ixekizumab (Taltz) and secukinumab (Cosentyx) in patients with moderate to severe plaque psoriasis.

Why this matters

  • Data on drug survival for biologics targeting interleukin 17 are scarce.

Key results

  • 40.7% of patients who received secukinumab and 12.9% of patients who received ixekizumab were biologic-naive.
  • Mean number of previous biologic treatments before initiation of secukinumab or ixekizumab were 1.3 and 3.6, respectively (P<.0001>
  • 15.8% of patients treated with secukinumab and 12.9% of patients treated with ixekizumab discontinued therapy in the first 12 months (P=.075).
  • 23.5% of biologic -naive patients treated with secukinumab and 0% of biologic -naive patients treated with ixekizumab discontinued therapy (P=.136).

Study design

  • 430 patients with moderate to severe plaque psoriasis from the Dermbio database, 368 treated with secukinumab and 62 treated with ixekizumab, were analyzed for drug survival.
  • Funding: None.

Limitations

  • Only 62 patients treated with ixekizumab vs 368 treated with secukinumab.
  • Although  0% of biologic-naive patients treated with ixekizumab discontinued therapy (vs 23.5% treated with secukinumab), only 12.9% of them were biologic-naive (vs 40.7% treated with secukinumab).